AbbVie stock: fundamental analysis
Stocks · ABBV · Healthcare
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. Below are its fundamentals, explained in the order worth reading them: business quality, debt, growth and, last, whether the price is reasonable.
- Price: 263.96 USD
- Market cap: 466.4B USD
Data as of September 18, 2026 · Yahoo Finance
Quick read
Business quality
No ROE available: AbbVie has negative equity or the figure is not published, which is common in companies with large buybacks.
Financial health
Net debt/EBITDA of 2.1x: moderate leverage, manageable for stable businesses such as utilities or infrastructure.
Growth
Revenue is growing 10.2% year on year: a solid pace. Earnings are up 290.4%.
Valuation
It trades at a P/E of 74.6, above the 33.9 median of the healthcare companies we track. On expected earnings the P/E falls to 16.2: the market expects profits to rise. Paying more can be justified by faster growth or a higher-quality business.
Dividend
Dividend yield of 2.6% (6.92 USD per share per year) with a payout ratio of 190.4%. It pays out nearly all (or more) of its earnings: watch whether the dividend is sustainable.
Tools
All metrics
| AbbVie | Sector median | |
|---|---|---|
| Business quality | ||
| ROE | — | 25.7% |
| ROA | 10.5% | 9.0% |
| Gross margin | 72.8% | 70.5% |
| Operating margin | 40.0% | 28.5% |
| Net margin | 9.8% | 15.6% |
| Financial health | ||
| Net debt/EBITDA | 2.1x | 2.0x |
| Debt/equity | — | 0.7x |
| Current ratio | 0.8x | 1.3x |
| Growth | ||
| Revenue growth | 10.2% | 10.2% |
| Earnings growth | 290.4% | 139.8% |
| Valuation | ||
| P/E ratio | 74.6x | 33.9x |
| Forward P/E | 16.2x | 16.7x |
| EV/EBITDA | 17.3x | 17.0x |
| Price/book | — | 4.2x |
| FCF yield | 3.6% | 4.7% |
| Dividend | ||
| Dividend yield | 2.6% | 1.8% |
| Payout ratio | 190.4% | 48.0% |
| Beta (volatility) | 0.3x | 0.3x |
Frequently asked questions
What is AbbVie's P/E ratio?
AbbVie's P/E is 74.6 based on trailing 12-month earnings and 16.2 on expected earnings. The median for its sector among the companies we track is 33.9. Data as of September 18, 2026.
What dividend does AbbVie pay?
Dividend yield of 2.6% (6.92 USD per share per year) with a payout ratio of 190.4%. It pays out nearly all (or more) of its earnings: watch whether the dividend is sustainable.
Is AbbVie stock expensive?
It trades at a P/E of 74.6, above the 33.9 median of the healthcare companies we track. On expected earnings the P/E falls to 16.2: the market expects profits to rise. Paying more can be justified by faster growth or a higher-quality business. This is an educational reading based on ratios, not a buy or sell recommendation.
Does AbbVie have a lot of debt?
Net debt/EBITDA of 2.1x: moderate leverage, manageable for stable businesses such as utilities or infrastructure.
What is AbbVie's market cap?
AbbVie has a market cap of 466.4B USD and its shares trade at 263.96 USD, with a 52-week range of 190.75 USD to 267.47 USD (data as of September 18, 2026).
Other companies in the sector
Trailing 12-month metrics. Educational content, not investment advice.